284 related articles for article (PubMed ID: 2190321)
1. Current status of iron chelation therapy with deferoxamine.
Cohen A
Semin Hematol; 1990 Apr; 27(2):86-90. PubMed ID: 2190321
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
3. Oral iron chelators.
Nathan DG; Piomelli S
Semin Hematol; 1990 Apr; 27(2):83-5. PubMed ID: 2190320
[No Abstract] [Full Text] [Related]
4. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
[TBL] [Abstract][Full Text] [Related]
5. Overview of iron chelation therapy with desferrioxamine and deferiprone.
Cappellini MD; Musallam KM; Taher AT
Hemoglobin; 2009; 33 Suppl 1():S58-69. PubMed ID: 20001633
[TBL] [Abstract][Full Text] [Related]
6. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
[No Abstract] [Full Text] [Related]
7. Combined iron chelation therapy.
Galanello R; Agus A; Campus S; Danjou F; Giardina PJ; Grady RW
Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
[TBL] [Abstract][Full Text] [Related]
8. Iron-chelation therapy with oral chelators in patients with thalassemia major.
Uygun V; Kurtoglu E
Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010
[TBL] [Abstract][Full Text] [Related]
9. Current recommendations for chelation for transfusion-dependent thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2016 Mar; 1368(1):107-14. PubMed ID: 27186943
[TBL] [Abstract][Full Text] [Related]
10. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
11. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
12. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
15. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ; Grady RW
Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
[TBL] [Abstract][Full Text] [Related]
16. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
Boturao-Neto E; Marcopito LF; Zago MA
Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
[TBL] [Abstract][Full Text] [Related]
17. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
18. The Role of Deferiprone in Iron Chelation.
Hider RC; Hoffbrand AV
N Engl J Med; 2018 Nov; 379(22):2140-2150. PubMed ID: 30485781
[No Abstract] [Full Text] [Related]
19. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Diamantidis MD; Neokleous N; Agapidou A; Vetsiou E; Manafas A; Fotiou P; Vlachaki E
Int J Hematol; 2016 May; 103(5):537-44. PubMed ID: 26861970
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
